NASDAQ:DARE Dare Bioscience (DARE) Stock Price, News & Analysis $1.88 -0.30 (-13.76%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.95 +0.07 (+3.72%) As of 06/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dare Bioscience Stock (NASDAQ:DARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dare Bioscience alerts:Sign Up Key Stats Today's Range$1.86▼$2.1950-Day Range$1.51▼$3.2752-Week Range$1.27▼$9.19Volume450,663 shsAverage Volume437,456 shsMarket Capitalization$28.16 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use. In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market. Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.AI Generated. May Contain Errors. Read More Dare Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreDARE MarketRank™: Dare Bioscience scored higher than 33% of companies evaluated by MarketBeat, and ranked 596th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDare Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDare Bioscience has a consensus price target of $10.00, representing about 431.9% upside from its current price of $1.88.Amount of Analyst CoverageDare Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Dare Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dare Bioscience are expected to grow in the coming year, from ($0.97) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dare Bioscience is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dare Bioscience is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDare Bioscience has a P/B Ratio of 9.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dare Bioscience's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.51% of the float of Dare Bioscience has been sold short.Short Interest Ratio / Days to CoverDare Bioscience has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dare Bioscience has recently increased by 120.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDare Bioscience does not currently pay a dividend.Dividend GrowthDare Bioscience does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Dare Bioscience this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dare Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders4.10% of the stock of Dare Bioscience is held by insiders.Percentage Held by Institutions6.70% of the stock of Dare Bioscience is held by institutions.Read more about Dare Bioscience's insider trading history. Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dare Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DARE Stock News HeadlinesDaré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic CapsulesJune 4 at 6:29 PM | finance.yahoo.comDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of ...May 26, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerMay 26, 2026 | globenewswire.comDaré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesMay 18, 2026 | globenewswire.comDaré Bioscience, Inc.: Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | finanznachrichten.deDaré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in JuneMay 15, 2026 | msn.comDare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...May 15, 2026 | finance.yahoo.comSee More Headlines DARE Stock Analysis - Frequently Asked Questions How have DARE shares performed this year? Dare Bioscience's stock was trading at $1.93 at the beginning of 2026. Since then, DARE shares have decreased by 2.6% and is now trading at $1.88. How were Dare Bioscience's earnings last quarter? Dare Bioscience, Inc. (NASDAQ:DARE) announced its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.13. The biotechnology company earned $0.15 million during the quarter, compared to analysts' expectations of $0.03 million. Read the conference call transcript. When did Dare Bioscience's stock split? Dare Bioscience shares reverse split on the morning of Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Dare Bioscience IPO? Dare Bioscience (DARE) raised $102 million in an initial public offering (IPO) on Thursday, April 10th 2014. The company issued 8,500,000 shares at a price of $11.00-$13.00 per share. How do I buy shares of Dare Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dare Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/14/2026Today6/05/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 8 days, DARE's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DARE CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees30Year Founded2006Price Target and Rating Average Price Target for Dare Bioscience$10.00 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+431.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.40 million Net MarginsN/A Pretax Margin-1,038.08% Return on EquityN/A Return on Assets-46.22% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$1.03 million Price / Sales27.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book9.40Miscellaneous Outstanding Shares14,980,000Free Float14,366,000Market Cap$28.16 million OptionableNot Optionable Beta1.07 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:DARE) was last updated on 6/6/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredIn 30 days, you'll wish you'd read this emailA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredShe called ASTS before it ran 133%. Here's the system behind it.Danielle Shay called AST SpaceMobile on Fox Business before it ran 133% - and found NBIS at $54 before it gapp...Simpler Trading | SponsoredWhy is this free?Simple Options Trading For Beginners normally sells for $29.97 - but right now Bill Poulos has opened a free w...Profits Run | SponsoredYou own these two timebombs — and can’t sell themTwo blue-chip stocks with a combined $100 billion market cap are sitting inside VOO, SPY, FXAIX, and virtually...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
